Malignant cardiac tumors: Diagnosis and treatment

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 485-500

  Lestuzzi, Chiara ^a   De Paoli, Antonino ^a   Baresic, Tanja ^a   Miolo, Gianmaria ^a   Buonadonna, Angela ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cardiac lymphoma; Cardiac malignancy; Cardiac radiotherapy; Cardiac sarcomas; Cardiac tumors; Chemotherapy; Malignant cardiac tumors; Non Hodgkin lymphoma; Sarcoma; Surgery

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CARDIOLOGIST; FOLLOW UP; HEART SARCOMA; HEART TUMOR; HUMAN; MALIGNANT CARDIAC TUMOR; NONHODGKIN LYMPHOMA; PATHOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; CARDIAC IMAGING; HEART NEOPLASMS; LYMPHOMA, NON-HODGKIN; SARCOMA;

CARDIAC IMAGING TECHNIQUES; HEART NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; SARCOMA;

EID: 84939420160     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.15.10     Document Type: Review

References (84)

1. Valente ML, Rizzo S, Leone O, Basso C. Primary malignant tumors of the heart. In: Cardiac Tumor Pathology. Basso C, Valente ML, Thiene G (Eds). Springer (Humana Press), New York, NY, USA, 73-89 (2013).
2. Miguel CE, Bestetti RB. Primary cardiac lymphoma. Int. J. Cardiol. 149, 358-363 (2011).
3. Butany J, Naseemuddin A, Nair G. M, Catton C, Yau T. Cardiac tumours: diagnosis and treatment. Lancet Oncol. 6, 219-228 (2005).
4. Jain D, Maleszewski JJ, Halushka MK. Benign cardiac tumors and tumorlike conditions. Ann. Diagn. Pathol. 14, 215-230 (2010).
5. Goswami KC, Shrivastava S, Bahl VK, Saxena A, Manchanda SC, Wasir HS. Cardiac myxomas: clinical and echocardiographic profile. Int. J. Cardiol. 63, 251-259 (1998).
6. Mazzola A, Spano JP, Valente M et al. Leiomyosarcoma of the left atrium mimicking a left atrial myxoma. J. Thorac. Cardiovasc. Surg. 131, 224-226 (2006).
7. Tao TY, Yahyavi-Firouz-Abadi N, Singh GK, Bhalla S. Pediatric cardiac tumors: clinical and imaging features. Radiographics 34, 1031-1046 (2014).
8. Lestuzzi C, Piazza R, Pavan D, Comoretto M, Nicolosi GL. Masse intracavitarie e paracardiache. In: Manuale di ecocardiografia clinica (Volume 2). Nicolosi GL, Antonini-Canterin F, Pavan D, Piazza R (Eds). Piccin Nuova Libraria S. p. A Padova, Italy (2015).
9. Lassau N, Chami L, Chebil M et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov. Med. 11 (56), 18-24 (2011).
10. Li SY, Huang PT, Xu HS et al. Enhanced intensity on preoperative double contrastenhanced sonography as a useful indicator of lymph node metastasis in patients with gastric cancer. J. Ultrasound Med. 33, 1773-1781 (2014).
11. Peters PJ, Reinhardt S. The echocardiographic evaluation of intracardiac masses: a review. J. Am. Soc. Echocardiogr. 19, 230-240 (2006).
12. Zaragoza-Macias E, Chen MA, Gill EA. Real time three-dimensional echocardiography evaluation of intracardiac masses. Echocardiography 29, 207-219 (2012).
13. Plana JC. Three-dimensional echocardiography in the assessment of cardiac tumors: the added value of the extra dimension. Methodist Debakey Cardiovasc. J. 6, 12-19 (2010).
14. Rajiah P, Kanne JP, Kalahasti V, Schoenhagen P. Computed tomography of cardiac and pericardiac masses. J. Cardiovasc. Comput. Tomogr. 5, 16-29 (2011).
15. Hoey E, Ganeshan A, Nader K, Randhawa K, Watkin R. Cardiac neoplasms and pseudotumors: imaging findings on multidetector CT angiography. Diagn. Interv. Radiol. 18, 67-77 (2012).
16. Kassop D, Donovan MS, Cheezum MK et al. Cardiac masses on cardiac CT: a review. Curr. Cardiovasc. Imaging Rep. 7, 9281 (2014).
17. Buckley O, Madan R, Kwong R, Rybicki FJ, Hunsaker A. Cardiac masses, part 1: imaging strategies and technical considerations. AJR Am. J. Roentgenol. 197, W837-W841 (2011).
18. Randhawa K, Ganeshan A, Hoey ET. Magnetic resonance imaging of cardiac tumors: part 1, sequences, protocols, and benign tumors. Curr. Probl. Diagn. Radiol. 40, 158-168 (2011).
19. Bauner KU, Sourbron S, Picciolo M et al. MR first pass perfusion of benign and malignant cardiac tumours-significant differences and diagnostic accuracy. Eur. Radiol. 22, 73-82 (2012).
20. Attili AK, Chew FS. Imaging of cardiac masses and myocardial disease: selfassessment module. AJR Am. J. Roentgenol. 188 (6 Suppl.), S21 (2007).
21. Pazos-López P, Pozo E, Siqueira ME et al. Value of CMR for the differential diagnosis of cardiac masses. JACC Cardiovasc. Imaging 7 (9), 896-905 (2014).
22. Maurer AH, Burshteyn M, Adler LP, Steiner RM. How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET/CT. Radiographics 31 (5), 1287-1305 (2011).
23. Rahbar K, Seifarth H, Schäfers M et al. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J. Nucl. Med. 53, 856-863 (2012).
24. Benz MR, Dry SM, Eilber FC et al. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J. Nucl. Med. 51, 1174-1181 (2010).
25. Israel O, Weiler-Sagie M, Rispler S et al. PET/CT quantitation of the effect of patient-related factors on cardiac 18F-FDG uptake. J. Nucl. Med. 48 234-239 (2007).
26. Lin EC, Alavi A. Normal variants and benign findings. In: PET And PET/CT. A Clinical Guide. (2nd Edition). Lin EC, Alavi A (Eds). Thieme, New York, NY, USA (2009).
27. Korn RL, Coates A, Millstine J. The role of glucose and FDG metabolism in the interpretation of PET studies. In: PET And PET/CT. A Clinical Guide. (2nd Edition). Lin EC, Alavi A (Eds). Thieme, New York, NY, USA (2009).
28. Loft A, Jensen KE, Löfgren J, Daugaard S, Petersen MM. PET/MRI for preoperative planning in patients with soft tissue sarcoma: a technical report of two patients. Case Rep. Med. 2013, 791078 (2013).
29. Nensa F, Schlosser T. Cardiovascular hybrid imaging using PET/MRI. Rofo 86 (12), 1094-1101 (2014).
30. Watanabe R. Tomita N, Takeuchi K et al. SUVmax in FDG-PET and the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma. Leuk. Lymph. 51, 279-283 ((2010)).
31. World Health Organization Classification Of Tumors: Pathology And Genetics Of Tumours Of The Lung, Pleura, Thymus And Heart. Trawis WD, Brambilla E, Muller-Hermelink HK, Harris CC (Eds). ARC Press, Lyon, France, 250 (2004).
32. Orlandi A, Ferlosio A, Roselli M, Chiariello L, Spagnoli LG. Cardiac sarcomas: an update. J. Thorac. Oncol. 5, 1483-1489 (2010).
33. Neuville A, Ranchère-Vince D, Dei Tos AP et al. Impact of molecular analysis on the final sarcoma diagnosis: a study on 763 cases collected during a European Epidemiological Study. Am. J. Surg. Pathol. 37 (8), 1259-1268 (2013).
34. Neuville A, Collin F, Bruneval P et al. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas. Am. J. Surg. Pathol. 38, 461-469 (2014).
35. Dei Tos AP. A current perspective on the role for molecular studies in soft tissue tumor pathology. Semin. Diagn. Pathol. 30, 375-381 (2013).
36. Donsbeck A-V, Ranchere D, Coindre J-M, Le Gall F, Cordier J-F, Loire R. Primary cardiac sarcomas: an immunohistochemical and grading study with long-term follow-up of 24 cases. Histopathology 34, 295-304 (1999).
37. Orlandi A, Spagnoli LG. Novelties in immunoistochemical and molecular study of cardiac tumors. In: Cardiac Tumor Pathology. Basso C, Valente ML, Thiene G (Eds). Springer (Humana Press), New York, NY, USA 183-193 (2013).
38. Basso C, Stefani A, Calabrese F, Fasoli G, Valente M. Primary right atrial fibrosarcoma diagnosed by endocardial biopsy. Am. Heart J. 131, 399-402 (1996).
39. Cornelis F, Silk M, Schoder H et al. Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities. Eur. J. Nucl. Med. Mol. Imaging 41 (12), 2265-2272 (2014).
40. Miguel CE, Bestetti RB. Primary cardiac lymphoma. Int. J. Cardiol. 149, 358-363 (2011).
41. Ray-Coquard I, Montesco MC, Coindre JM et al. Conticanet group. Sarcoma: concordance between initial diagnosis and centralized expert review in a populationbased study within three European regions. Ann. Oncol. 23, 2442-2449 (2012).
42. Lestuzzi C, Spina M, Martellotta F, Carbone A. Massive myocardial infiltration by HIV-related non-Hodgkin lymphoma: echocardiographic aspects at diagnosis and at follow-up. J. Cardiovasc. Med. (Hagerstown). 13, 836-838 (2012).
43. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J. Clin. 60, 393-408 (2010).
44. Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v172-v174 (2010).
45. Llombart-Cussac A, Pivot X, Contesso G et al. Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br. J. Cancer 78, 1624-1628 (1998).
46. Debourdeau P, Gligorov J, Teixeira L, Aletti M, Zammit C. Tumeurs cardiaques malignes. Bull. Cancer 91, S136-S146 (2004).
47. Simpson L, Kumar SK, Okuno SH et al. Malignant primary cardiac tumors. Review of a single institution experience. Cancer 112, 2440-2446 (2008).
48. Kim CH, Dancer JY, Coffey D, et al. Clinicopathologic study of 24 patients with primary cardiac sarcomas: a 10 year single institution experience. Hum. Pathol. 39, 933-938 (2008).
49. Agaimy A, Rösch J, Weyand M, Strecker T. Primary and metastatic cardiac sarcomas: a year experience at a German heart center. Int. J. Clin. Exp. Pathol. 5, 928-938 (2012).
50. Truong PT, Jones SO, Martens B et al. Treatment and outcomes in adult patients with primary cardiac sarcoma: the British Columbia Cancer Agency experience. Ann. Surg. Oncol. 16, 3358-3365 (2009).
51. Hamidi M, Moody JS, Weigel TL, Kozak KR. Primary cardiac sarcoma. Ann. Thorac. Surg. 90, 176-181 (2010).
52. Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma 2010, 506182 (2010).
53. Stucky CC, Wasif N, Ashman JB, Pockaj BA, Gunderson LL, Gray RJ. Excellent local control with preoperative radiation therapy, surgical resection, and intra-operative electron radiation therapy for retroperitoneal sarcoma. J. Surg. Oncol. 109, 798-803 (2014).
54. Le Cesne A, Ouali M, Leahy MG et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC Phase III clinical trials. Ann. Oncol. 25 (12), 2425-2432 (2014)
55. Mayer F, Aebert H, Rudert M et al. Primary malignant sarcomas of the heart and great vessels in adult patients. A single-center experience. Oncologist 12, 1134-1142 (2007).
56. Vaporciyan A, Reardon MJ. Right heart sarcomas. Methodist Debakey Cardiovasc. J. 6, 44-48 (2010).
57. Putnam JB, Sweeney MS, Colon R, Lanza LA, Frazier OH, Cooley DA. Primary cardiac sarcomas. Ann. Thorac. Surg. 51, 906-910 (1991).
58. Stefanovski PD, Bidoli E, De Paoli A et al. Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur. J. Surg. Oncol. 28, 153-164 (2002).
59. Tsukushi S, Nishida Y, Urakawa H, Kozawa E, Ishiguro N. Prognostic significance of histological invasion in high grade soft tissue sarcomas. Springerplus 3, 544 (2014).
60. Blackmon SH, Rice DC, Correa AM et al. Management of primary pulmonary artery sarcomas. Ann. Thorac. Surg. 87 (3), 977-984 (2009).
61. Rice DC, Reardon MJ. Left heart sarcomas. Methodist Debakey Cardiovasc. J. 6, 49-56 (2010).
62. Ramlawi B, Al-Jabbari O, Blau LN et al. Autotransplantation for the resection of complex left heart tumors. Ann. Thorac. Surg. 98, 863-868 (2014).
63. Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft-tissue sarcomas: results of Phase II and pilot studies-dose response and schedule dependence. J. Clin. Oncol. 15, 2378-2384 (1997).
64. Lyseng-Williamson KA, Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a guide to its use in various malignancies. BioDrugs 27, 533-540 (2013).
65. Grenader T, Goldberg A, Hadas-Halperin I, Gabizon A. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anticancer Drugs 20, 15-20 (2009).
66. D'Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br. J. Cancer 111, 646-650 (2014).
67. Leporini C, Patanè M, Saullo F et al. A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations. BioDrugs 28 (6), 499-511 (2014).
68. Ganjoo K, Jacobs C. Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer 116 (5), 1177-1183 (2010).
69. Penel N, Marréaud S, Robin YM, Hohenberger P. Angiosarcoma: state of the art and perspectives. Crit. Rev. Oncol. Hematol. 80, 257-263 (2011).
70. van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet 379, 1879-1886 (2012).
71. Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 44, 2433-2436 (2008).
72. Kopp HG, Patel S, Brücher B, Hartmann JT. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. Am. J. Clin. Dermatol. 9 (4), 207-217 (2008).
73. Schöffski P, Cornillie J, Wozniak A, Li H, Hompes D. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol. Res. Treat. 37, 355-362 (2014).
74. Basavaraju SR, Easterly CE. Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. Med. Phys. 29, 2391-2403 (2002).
75. Thariat J, Clément-Colmou K, Vogin G et al. Radiation therapy of cardiac sarcomas. Cancer Radiother. 18, 125-131 (2014).
76. Isambert N, Ray-Coquard I, Italiano A et al. Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. Eur. J. Cancer 50, 128-136 (2014).
77. Lestuzzi C, Buonadonna A, Scalone S et al. Feasibility of multimodality treatment for cardiac sarcomas. Presented at: European Society of Cardiology Congress. Barcelona, Spain, 30 August-3 September 2014.
78. Li H, Xu D, Chen Z et al. Prognostic analysis for survival after resections of localized primary cardiac sarcomas: a single-institution experience. Ann. Thorac. Surg. 97, 1379-1385 (2014).
79. Blackmon SH, Reardon MJ. Pulmonary artery sarcoma. Methodist Debakey Cardiovasc. J. 6, 38-43 (2010).
80. Wang M, Fu G, Jiang H, Zeng K, Hua P. Multimodality treatment for cardiac angiosarcoma. Intern. Med. 53, 1949-1953 (2014).
81. Burke AP, Cowan D, Virmani R. Primary sarcomas of the heart. Cancer 69, 387-395 (1992).
82. Bakaeen FG, Jaroszewski DE, Rice DC et al. Outcomes after surgical resection of cardiac sarcoma in the multimodality treatment era. J. Thorac. Cardiovasc. Surg. 137, 1454-1460 (2009).
83. Randhawa JS, Budd GT, Randhawa M et al. Primary cardiac sarcoma: 25-year cleveland clinic experience. Am. J. Clin. Oncol. doi:10. 1097/COC. 0000000000000106 (2014) (Epub ahead of print).
84. Ravi V, Benjamin RS. Systemic therapy for cardiac sarcomas. Methodist Debakey Cardiovasc. J. 6, 57-60 (2010).